Microbot Medical Financials

MBOT Stock  USD 1.52  0.04  2.56%   
Microbot Medical is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March. At this time, Microbot Medical's Property Plant Equipment is comparatively stable compared to the past year. Capital Lease Obligations is likely to gain to about 432.7 K in 2025, whereas Other Current Liabilities is likely to drop slightly above 2.6 M in 2025. Key indicators impacting Microbot Medical's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio1.791.88
Notably Down
Very volatile
The financial analysis of Microbot Medical is a critical element in measuring its lifeblood. Investors should not minimize Microbot Medical's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Net Income

(12.97 Million)

  
Please note, the imprecision that can be found in Microbot Medical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Microbot Medical. Check Microbot Medical's Beneish M Score to see the likelihood of Microbot Medical's management manipulating its earnings.

Microbot Medical Stock Summary

Microbot Medical competes with Intuitive Surgical, Predictive Oncology, STAAR Surgical, Becton Dickinson, and West Pharmaceutical. Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts. Microbot Medical operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 20 people.
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS59503A2042
CUSIP59503A204 85857R204 59503A105 85857R303 85857R105 232923102
LocationMassachusetts; U.S.A
Business Address288 Grove Street,
SectorHealth Care Equipment & Supplies
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitemicrobotmedical.com
Phone781 875 3605
CurrencyUSD - US Dollar

Microbot Medical Key Financial Ratios

Microbot Medical Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets26.3M16.8M9.5M8.3M7.5M7.1M
Other Current Liab696K1.4M1.7M3.2M3.7M2.6M
Net Debt(18.8M)(12.8M)(2.0M)(2.2M)(2.0M)(2.1M)
Retained Earnings(44.3M)(55.6M)(68.8M)(79.5M)(71.6M)(75.1M)
Accounts Payable275K279K116K357K321.3K489.2K
Cash19.7M13.5M2.4M2.5M2.8M2.7M
Net Receivables340K174K103K1.3M1.5M1.6M
Other Current Assets265K213K609K243K218.7K207.8K
Total Liab2.0M2.4M2.2M3.8M3.4M3.3M
Total Current Assets25.3M15.9M8.8M7.9M7.1M6.8M
Short Term Debt374K278K283K191K219.7K208.7K
Inventory(5K)(174K)(103K)(42K)(37.8K)(39.7K)
Net Tangible Assets31.5M24.3M14.4M7.3M8.4M11.1M

Microbot Medical Key Income Statement Accounts

The reason investors look at the income statement is to determine what Microbot Medical's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
202020212022202320242025 (projected)
Interest Expense103K80K44K131.3M151.0M158.5M
Gross Profit(68K)(76K)(102K)(106K)(95.4K)(90.6K)
Operating Income(9.1M)(11.4M)(13.3M)(9.9M)(8.9M)(8.4M)
Ebit(9.1M)(11.4M)(13.3M)(10.7M)(9.7M)(10.1M)
Ebitda(9.0M)(11.3M)(13.2M)(10.6M)(9.6M)(10.0M)
Cost Of Revenue68K76K102K106K95.4K90.6K
Income Before Tax(9.2M)(11.3M)(13.2M)(10.7M)(9.7M)(10.1M)
Net Income(9.2M)(11.3M)104.8M(10.7M)(12.4M)(13.0M)
Income Tax Expense103K80K(44K)(118M)(106.2M)(100.9M)
Research Development3.4M6.2M7.7M5.6M5.1M9.5M
Interest Income16K103K54K212K243.8K256.0K
Net Interest Income(80K)44K54K212K243.8K256.0K

Microbot Medical Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash(13.4M)(6.2M)(11.1M)(2K)(1.8K)(1.7K)
Free Cash Flow(7.3M)(9.4M)(11.6M)(8.6M)(7.7M)(8.1M)
Depreciation68K76K102K106K95.4K90.6K
Other Non Cash Items(70K)1.5M(7K)718K646.2K678.5K
Capital Expenditures91K69K84K33K29.7K28.2K
Net Income(9.2M)(11.3M)(13.2M)(10.7M)(9.7M)(10.1M)
End Period Cash Flow19.7M13.6M2.5M2.5M2.3M2.2M
Investments(2.8M)3.2M(3.8M)(4.7M)(5.4M)(5.7M)
Change To Netincome1.4M1.0M1.9M1.4M1.2M1.5M

Microbot Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Microbot Medical's current stock value. Our valuation model uses many indicators to compare Microbot Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Microbot Medical competition to find correlations between indicators driving Microbot Medical's intrinsic value. More Info.
Microbot Medical is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Microbot Medical's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Microbot Medical by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Microbot Medical Systematic Risk

Microbot Medical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Microbot Medical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Microbot Medical correlated with the market. If Beta is less than 0 Microbot Medical generally moves in the opposite direction as compared to the market. If Microbot Medical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Microbot Medical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Microbot Medical is generally in the same direction as the market. If Beta > 1 Microbot Medical moves generally in the same direction as, but more than the movement of the benchmark.

Microbot Medical Thematic Clasifications

Microbot Medical is part of several thematic ideas from Drugs to Office Supplies. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Microbot Medical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Microbot Medical's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Microbot Medical growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0159

At this time, Microbot Medical's Price Earnings To Growth Ratio is comparatively stable compared to the past year.

Microbot Medical February 25, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Microbot Medical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Microbot Medical. We use our internally-developed statistical techniques to arrive at the intrinsic value of Microbot Medical based on widely used predictive technical indicators. In general, we focus on analyzing Microbot Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Microbot Medical's daily price indicators and compare them against related drivers.

Additional Tools for Microbot Stock Analysis

When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.